Form 4: Cidara Therapeutics CEO Acquires 275,000 Stock Options

Cidara Therapeutics CEO Jeffrey Stein was granted 275,000 employee stock options on March 31, 2025, according to a Form 4 filing with the SEC.

Summary

• Jeffrey Stein, the President and CEO of Cidara Therapeutics, Inc., acquired 275,000 employee stock options on March 31, 2025.
• The options have an exercise price of $21.54.
• The options vest in 36 equal monthly installments starting from March 31, 2025, and expire on March 30, 2035.
• The Form 4 filing was signed by Shane Ward, Attorney-in-Fact, on April 02, 2025.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard executive compensation practice. The grant itself doesn't inherently indicate positive or negative performance, but rather an incentive structure.

Positives

• The acquisition of stock options by the CEO could align his interests with those of the shareholders, potentially driving company performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align management interests with shareholder value.

Comparison to Industry Standards

• Executive compensation packages, including stock options, vary widely across the biotechnology industry depending on company size, stage of development, and performance.
• Comparing Cidara's executive compensation to peers like BioCryst Pharmaceuticals or Nabriva Therapeutics would provide a better understanding of whether the size and structure of the grant are in line with industry norms.

Stakeholder Impact

• The stock option grant could incentivize the CEO to improve company performance, potentially benefiting shareholders.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Cidara Therapeutics, Jeffrey Stein, stock options, Form 4, SEC, executive compensation, CDTX